Examining the potential preventative effects of minocycline prescribed for acne on the incidence of severe mental illnesses: A historical cohort study

Abstract

Background:

Animal studies suggest that the antibiotic and microglial activation inhibitor, minocycline, is likely to have a protective effect against the emergence of psychosis but evidence from human studies is lacking. The aim of this study is to examine the effects of exposure to minocycline during adolescence on the later incidence of severe mental illness (SMI).

Methods:

A historical cohort study using electronic primary care data was conducted to assess the association between exposure to minocycline during adolescence and incidence of SMI. The Incidence Rate Ratio (IRR) was measured using Poisson regression adjusted for age, gender, time of exposure, socioeconomic deprivation status, calendar year and co-medications.

Results:

Early minocycline prescription (n=13,248) did not affect the incidence of SMI compared with non-prescription of minocycline (n=14,393), regardless of gender or whether or not the data were filtered according to a minimum exposure period (minimum period: IRR 0.96; 95% CI 0.68–1.36; p=0.821; no minimum period: IRR 1.08; 95% CI 0.83–1.42; p=0.566).

Conclusions:

Exposure to minocycline for acne treatment during adolescence appears to have no effect on the incidence of SMI.

Keywords

Schizophrenia drug repurposing preventative effect tetracycline

Get full access to this article

View all access options for this article.

References

Akhondzadeh

Tabatabaee

Amini

et al (2007) Celecoxib as adjunctive therapy in schizophrenia: A double-blind, randomized and placebo-controlled trial. Schizophr Res 90: 179–185.

Austin

(2009) Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simul Comput 38: 1228–1234.

Bossong

Niesink

RJM

(2010) Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog Neurobiol 92: 370–385.

Bump

Enning

Leweke

(2013) Repurposed drugs for the treatment of schizophrenia and bipolar disorders. Curr Top Med Chem 13: 2364–2385.

Castle

McGranth

Kulkarni

(2000) Women and Schizophrenia. Cambridge: Cambridge University Press.

Chaudhry

Hallak

Husain

et al (2012) Minocycline benefits negative symptoms in early schizophrenia: A randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 26: 1185–1193.

Chaudhry

Husain

ur Rahman

et al (2015) A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: Study protocol for a randomised controlled trial. Trials 16: 9.

Chaves

Marque

Maia-de-Oliveira

et al (2015) Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia. Schizophr Res 161: 439–445.

Domercq

Matute

(2004) Neuroprotection by tetracyclines. Trends Pharmacol Sci 25: 10–13.

10.

García Rodríguez

Pérez Gutthann

(2002) Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol 45: 419–425.

11.

Garner

Eady

Popescu

et al (2003) Minocycline for acne vulgaris: Efficacy and safety. Cochrane Database Syst Rev 1: CD002086.

12.

Garrido-Mesa

Zarzuelo

Gálvez

(2013) Minocycline: Far beyond an antibiotic. Br J Pharmacol 169: 337–352.

13.

Ghanizadeh

Dehbozorgi

OmraniSigaroodi

et al (2014) Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; A randomized placebo-controlled clinical trial. Recent Pat Inflamm Allergy Drug Discov 8: 211–215.

14.

Giovanoli

Engler

et al (2013) Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 339: 1095–1099.

15.

Giovanoli

Engler

et al (2016) Preventive effects of minocycline in a neurodevelopmental two-hit model with relevance to schizophrenia. Transl Psychiatry 6: e772.

16.

Hardoon

Hayes

Blackburn

et al (2013) Recording of severe mental illness in United Kingdom primary care, 2000–2010. PLoS One 8: e82365.

17.

Herrett

Thomas

Schoonen

et al (2010) Validation and validity of diagnoses in the General Practice Research Database: A systematic review. Br J Clin Pharmacol 69: 4–14.

18.

Hoirisch-Clapauch

Nardi

(2013) Psychiatric remission with warfarin: Should psychosis be addressed as plasminogen activator imbalance? Med Hypotheses 80: 137–141.

19.

Husain

Chaudhry

Rahman

et al (2017) Minocycline as an adjunct for treatment-resistant depressive symptoms: Study protocol for a pilot randomised controlled trial. J Psychopharmacol 31: 1166–1175.

20.

Joint Formulary Committee (2016) British National Formulary (Online). London: BMJ Group and Pharmaceutical Press. Available at: https://bnf.nice.org.uk/drug/minocycline.html#indicationsAndDoses (accessed October 2016).

21.

Jones

Watson

Fone

(2011) Animal models of schizophrenia. Br J Pharmacol 164: 1162–1194.

22.

Keller

Kum

Wehring

et al (2013) A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol 27: 337–342.

23.

Kelly

Sullivan

McEvoy

et al (2015) Adjunctive minocycline in clozapine-treated schizophrenia patients with persistent symptoms. J Clin Psychopharmacol 35: 374–381.

24.

Khodaie-Ardakani

M-R

Mirshafiee

Farokhnia

et al (2014) Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study. Psychiatry Res 215: 540–546.

25.

Kirkbride

Errazuriz

Croudace

et al (2012) Incidence of schizophrenia and other psychoses in england, 1950–2009: A systematic review and meta-analyses. PLoS One 7: e31660.

26.

Laan

Grobbee

Selten

J-P

et al (2010) Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: Results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 71: 520–527.

27.

Levkovitz

Levi

Braw

et al (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Res 1154: 154–162.

28.

Levkovitz

Mendlovich

Riwkes

et al (2010) A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 71: 138–149.

29.

Liu

Guo

et al (2014) Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: A double blind, randomized, controlled trial. Schizophr Res 153: 169–176.

30.

M-L

Pan

J-J

Teng

H-W

et al (2002) Metoclopramide-induced supersensitivity psychosis. Ann Pharmacother 36: 1387–1390.

31.

Ludot

Mouchabac

Ferreri

(2015) Inter-relationships between isotretinoin treatment and psychiatric disorders: Depression, bipolar disorder, anxiety, psychosis and suicide risks. World J Psychiatry 5: 222–227.

32.

Miyaoka

Wake

Furuya

et al (2012) Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study. Prog Neuropsychopharmacol Biol Psychiatry 37: 222–226.

33.

Monji

Kato

Mizoguchi

et al (2013) Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 42: 115–121.

34.

Monte

de Souza

McIntyre

et al (2013) Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol 27: 1032–1043.

35.

National Institute for Health and Care Excellence (2014) Clinical Knowledge Summaries: Acne vulgaris. Available at: http://cks.nice.org.uk/acne-vulgaris (accessed 6 November 2015).

36.

National Institute for Health and Care Excellence (2015) Key Therapeuctic Topics: Minocycline. Available at: https://www.nice.org.uk/advice/ktt11 (accessed October 2016).

37.

National Institute for Health and Care Excellence (2016). Available at: https://www.nice.org.uk/guidance (accessed October 2016).

38.

Oya

Kishi

Iwata

(2014) Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: A systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol 29: 483–491.

39.

Pedersen

Mors

Bertelsen

et al (2014) A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders. JAMA Psychiatry 71: 573–581.

40.

Shyu

Yuan

Lee

S-Y

et al (2015) Attention-deficit/hyperactivity disorder, methylphenidate use and the risk of developing schizophrenia spectrum disorders: A nationwide population-based study in Taiwan. Schizophr Res 168: 161–167.

41.

Suissa

Garbe

(2007) Primer: administrative health databases in observational studies of drug effects–advantages and disadvantages. Nat Clin Pract Rheumatol 3: 725–732.

42.

Sweetman

(2016) Martindale: The Complete Drug Reference (online). London: Pharmaceutical Press. Available at: http://www.medicinescomplete.com/ (accessed 4 October 2016).

43.

Takahashi

Sakai

et al (2016) Linking activation of microglia and peripheral monocytic cells to the pathophysiology of psychiatric disorders. Front Cell Neurosci 10: 144.

44.

Williams

van Staa

Puri

et al (2012) Recent advances in the utility and use of the general practice research database as an example of a UK primary care data resource. Ther Adv Drug Saf 3: 89–99.

45.

Xiang

Y-Q

Zheng

Wang

S-B

et al (2016) Adjunctive minocycline for schizophrenia: Ameta-analysis of randomized controlled trials. Eur Neuropsychopharmacol 27: 8–18.

46.

Zaenglein

Pathy

Schlosser

et al (2016) Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol 74: 945–973.e33.

47.

Zhang

Shirayama

Iyo

et al (2007) Minocycline Attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 32: 2004–2010.

48.

Zhang

Zhao

(2014) Profile of minocycline and its potential in the treatment of schizophrenia. Neuropsychiatr Dis Treat 10: 1103–1111.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.19 MB